Legal & General Group Plc Purchases New Shares in Repligen Corporation $RGEN

Legal & General Group Plc purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 68,988 shares of the biotechnology company’s stock, valued at approximately $9,413,000. Legal & General Group Plc owned 0.12% of Repligen at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC purchased a new stake in shares of Repligen in the third quarter valued at about $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen in the 4th quarter valued at about $36,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Repligen during the 2nd quarter valued at approximately $52,000. Farther Finance Advisors LLC raised its stake in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares during the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 104 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RGEN has been the topic of several analyst reports. Barclays lifted their target price on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Wells Fargo & Company lifted their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Finally, Evercore restated an “outperform” rating and set a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Repligen currently has an average rating of “Buy” and an average target price of $166.43.

Repligen Stock Down 6.1%

Repligen stock opened at $170.02 on Wednesday. The stock’s 50 day moving average price is $153.95 and its 200 day moving average price is $133.50. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73. The company has a market cap of $9.60 billion, a PE ratio of 232.90, a price-to-earnings-growth ratio of 3.30 and a beta of 1.04. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.Repligen’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.60% of the stock is owned by corporate insiders.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.